Cartesian Therapeutics’ Post

Tune into the next episode of #BioBlast with Carsten Brunn of Cartesian Therapeutics! We appreciate your time, and for sharing insights on the highly relevant trends impacting #biotech and #pharma in 2024 and beyond.

After productive time off including a trip to the Biotechnology Innovation Organization Conference in San Diego we're back with the next episode of #BioBlast!👏 👏 👏 Devin Zitelman connects with Carsten Brunn, President & CEO, Cartesian Therapeutics (NASDAQ: RNAC), a publicly traded, clinical-stage #biotech company pioneering #mRNA cell therapy for autoimmune diseases. The two discuss the company's $110M reverse-merger with Selecta Biosciences, plus: 🔎 Professional story and career "arcs" that inform his leadership style and management approach. ☕ The integration of founder (Murat Kalayoglu + Michael Singer) and executive teams, approach to culture-building and talent acquisition. 💉 Managing a pipeline of novel assets across multiple indications and phases of clinical trials. 🔭 Differences and advantages of hosting operations in #Boston and #Maryland including their biomanufacturing + GMP facilities. 💰 Trends in venture and development capital. ...and more! 📹 Tune in and subscribe to #BioBlast, now streaming on YouTube & Spotify for Podcasters plus anywhere you access your #podcasts. MassBio Maryland Tech Council Maryland Department of Commerce BioBuzz Nasdaq Frederick Innovative Technology Center, Inc Argot Partners Scheer Partners Velogic The National Institutes of Health Disclaimer: The views expressed in this promotion are based on personal opinions and should not be considered investment advice. Scheer Partners employs individuals that own shares in Cartesian Therapeutics stock.

Where does the power lie in Quince Therapeutics’ platform? It’s in our ability to harness a patient’s own biology with our proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology to deliver innovative therapeutics to those living with rare diseases.   We invite you to listen in as Dirk Thye, Quince’s CEO & CMO, describes what makes the AIDE technology behind our Phase 3 lead asset, EryDex, so powerful. By pioneering the delivery of drugs encapsulated in a patient’s own red blood cells, we’re looking to redefine the standard of care, first for chronic corticosteroid therapy, and later for other drugs, that will and meaningfully improve the quality of life for rare disease patients and their families.   For more information on Quince Therapeutics, contact ir@quincetx.com.   #Biotech #Raredisease #Innovation

Builders 🧱 w/ Thomas Miller - Co-Founder & CEO @ Iambic Therapeutics Tom Miller is a scientist and entrepreneur with focus on the nexus of AI, chemistry, and biology. He spent over 10 years as a tenured professor at Caltech, publishing more than 130 peer-reviewed articles and patents and receiving numerous awards for research excellence. Tom is co-founder and CEO of Iambic Therapeutics - previously known as Entos AI - disrupting the therapeutics landscape with a unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated drugs. The Iambic platform has been demonstrated to deliver best-in-class and first-in-class development candidates to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic has recently announced an oversubscribed $100m Series B raise to demonstrate that the company’s lead programs deliver clinical efficacy for patients with urgent unmet need. See our latest episode below... https://buff.ly/48QzyjW #AIinMedicine #MicrofluidicsTech #BiologicalDiscovery #LifeSciencesAdvancement #TranslationalResearch #DiagnosticTesting #Therapeutics #BiotechInnovation #STEMAdvancement

As R&D teams in #Pharma and #BioTech drive innovation with new modalities and personalized medicines, #TechOps face the challenge of removing roadblocks to #Commercialization – production costs and turnaround times. Geoffrey Zassenhaus shares how we helped the CMC team of a leading biotech collaborate to redesign its production processes to reduce costs by a factor of 25 and time to patient by 50%. https://lnkd.in/eDXbbbhf

Builders 🧱 w/ Tom Miller - Co-Founder & CEO @ Iambic Therapeutics Tom Miller is a scientist and entrepreneur with focus on the nexus of AI, chemistry, and biology. He spent over 10 years as a tenured professor at Caltech, publishing more than 130 peer-reviewed articles and patents and receiving numerous awards for research excellence. Tom is co-founder and CEO of Iambic Therapeutics - previously known as Entos AI - disrupting the therapeutics landscape with a unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated drugs. The Iambic platform has been demonstrated to deliver best-in-class and first-in-class development candidates to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic has recently announced an oversubscribed $100m Series B raise to demonstrate that the company’s lead programs deliver clinical efficacy for patients with urgent unmet need. See our latest episode below... https://buff.ly/48QzyjW #AIinMedicine #MicrofluidicsTech #BiologicalDiscovery #LifeSciencesAdvancement #TranslationalResearch #DiagnosticTesting #Therapeutics #BiotechInnovation #STEMAdvancement

Time is running out: Register now for the 24th BioEquity Europe, May 12-14 in San Sebastian, Spain. Join more than 280 CEOs and 260 investors at this destination event for biopharma decision-makers. ✅ Register (don't wait, it will sell out): https://lnkd.in/gSxxhu7 One area to highlight: Half the 130 presenting biotechs are new to the BioEquity stage. If you are an investor or BD&L leader, BioEquity is where you meet newcos that have caught the eye of BioCentury Inc. (and my colleague Jeff Cranmer). A few examples: ➢ Alder Therapeutics ➢ Ananda Scientific ➢ BioCorteX ➢ Bloomsbury Genetic Therapies ➢ Cellaïon ➢ Cumulus Oncology ➢ Curadh MTR Inc ➢ Gate2Brain ➢ Kudo Biotechnology ➢ Kynos Therapeutics ➢ Laverock Therapeutics ➢ MitoRx Therapeutics ➢ Oniria Therapeutics ➢ Sapient Therapeutics ➢ Serna Bio ➢ TAUC3 BIOLOGICS ➢ Tessellate BIO ➢ Traverse Biotech, Inc ➢ and many more.... ✅ Visit the Presenting Company Dashboard to review their pipelines, financings, deals, and more: https://lnkd.in/ducEqTW3 Please send a DM if you have questions about the event. I hope to see you in San Sebastian! #biotech #biopharma #venturecapital #drugdevelopment #businessdevelopment #pharma #BioEquityEurope

Tune into Iambic co-founder and CEO Thomas Miller discussing the genesis and future of Iambic on BIOS!

The latest episode of Raising Biotech is up, this time with Sparrow Pharmaceuticals, Inc. In this episode we learn that it's never too late to start a biotech as David A. Katz, founded Sparrow when he "should" have been retiring. David was able to raise $50 million in a Series A in 2020 to help fight the long standing (yet often forgotten) problem of patients suffering from steroid excess -- either from cortisol secreting tumors in Cushing's Syndrome or Autonomous Cortisol Secretion, or as side-effects from common glucocorticoid medications like prednisone and predisolone, which is pretty much every common autoimmune disease. This is another "trash to treasure" type story as David took a deprioritized drug out of a big pharma pipeline and is positioning it in three different clinical programs. David talks about his own journey as the company founder, what it was like to negotiate a drug license with big pharma, pitching to skeptical investors and he shares more details on each clinical trial program and future company visions. Also joining the podcast is Dr Peter Merkel, Chief of the Division of Rheumatology, Penn Medicine, University of Pennsylvania Health System as well as Dr Leon Henderson-MacLennan, MD, FACP, former medical internist and founder, inThought Research. These experienced experts give us more context on the drug's potential to fill an unmet need amidst an existing treatment landscape. This is quite an inspiring story, as it's taken a lot of patience and persistence to get Sparrow to this point and the company will soon be reaching an inflexion point as it plans for important data readouts this year. Listen (and find time stamps) here ⏯️: Website: https://lnkd.in/e2Affpuh Apple: https://lnkd.in/eGTiXaye Spotify: https://lnkd.in/ezCyJCyB This episode is proud to be partnered with Mindgram - a research tool powered by AI serving the global biopharma community. Raising Biotech listeners are able to get an exclusive free trial (link in show notes). OrbiMed RiverVest Venture Partners USVP #venturecapital #steroids #glucocorticoids #cortisol #cushings #autoimmunedisease

DGE announces the agenda for the ARTIFICIAL INTELLIGENCE for Life Sciences Compliance! Attend this groundbreaking conference that will exchange perspectives on how to manage and prioritize in the era of #AI. View the agenda today! #DGEvents #AIforLifeSciences #Compliance